Dianthus therapeutics to participate in three upcoming healthcare investor conferences

New york and waltham, mass., nov. 04, 2024 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and corporate overview presentations by marino garcia, chief executive officer, at the following healthcare investor conferences during november and december 2024:
DNTH Ratings Summary
DNTH Quant Ranking